Announcement of the project to be nominated for the 2022 Higher Education Scientific Research Outstanding Achievement Award

Date：

2022-04-29

The following projects completed by our unit intend to be nominated for the Ministry of Education Higher Education Scientific Research Outstanding Achievement          Award, and are hereby announced. The publicity period is from  April 29 , 2022   to May 09 , 2022.   If you have any objections to the publicized , please report to the office (the name of the scientific management department of the publicity unit).                                

 

Contact person and phone number:  Wang Zhongliang   0551-65732099

 

 

 

Completing unit (seal): Anhui Huibang Biological Engineering Co., Ltd. 

 

April 29 ,   2022 _ _  

 

Attachment: Announcement Content

 

Recommending the announcement of the Science and Technology Progress Award for Outstanding Scientific Research Achievements in Universities

project name

Development and application of diabetes molecular targets

Nominating unit (expert)

  Beijing Municipal Education Commission

Main Completion Unit

Capital medical university

Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences

Anhui Huibang Biological Engineering Co., Ltd.

 

1. The main person who completes the project:

Name

ranking

Technical titles

employer

complete unit

Main scientific and technological innovations for this project

contribution

Yang Jinkui

1

professor

Beijing Tongren Hospital Affiliated to Capital Medical University

Beijing Tongren Hospital Affiliated to Capital Medical University

作为学术带头人与项目负责人，全面负责项目、课题总体思路设计，把握研究方向，提出重点研究问题，组织人员安排。主要学术（技术）贡献：1.开展糖尿病发病机制研究，找到两个糖尿病治疗候选基因；2.发现了糖尿病肾病早期诊断标志物；3.开启了糖尿病视网膜病变筛查和诊疗新方法，开创性建立了微血管病变检测新方法；4.揭示了中国人群糖尿病视网膜病变患病率，建立全球最大的增殖期视网膜病变样本库；5.广泛开展国内学术推广活动，国际合作培养青年人才。

李于

2

研究员

中国科学院上海营养与健康研究所

中国科学院上海营养与健康研究所

作为项目负责人之一，进行了ATF/CREB家族调节肝细胞糖脂代谢与肝细胞增殖方面研究

王忠亮

3

 

安徽惠邦生物工程有限公司

安徽惠邦生物工程有限公司

主要贡献为将学术研究转换为产品，主导完成尿结合珠蛋白应用于糖尿病肾脏疾病的检测系统建立及其产业转换，将项目转化成取得医疗器械注册证的成熟检测系统，并进行产业化放大。

曹曦

4

副教授

首都医科大学附属北京同仁医院

首都医科大学附属北京同仁医院

1.进行了糖尿病发病机制ACE2糖脂代谢相关研究；2.参与了KCNH6与糖尿病发病机制相关研究；3.进行了光学相干断层扫描用于自然人群糖尿病视网膜病变流行病学调查研究；4.参与了糖尿病肾病早期诊断标志物的研究；5.参与了中国人群糖尿病视网膜病变患病率调查研究。

史婷婷

5

副主任医师

首都医科大学附属北京同仁医院

首都医科大学附属北京同仁医院

1.参与了ACE2和KCNH6与糖尿病发病机制相关研究；2.参与了糖尿病肾病早期诊断标志物的研究。

卢晶

6

副研究员

首都医科大学附属北京同仁医院

首都医科大学附属北京同仁医院

1.进行了KCNH6与糖尿病发病机制相关研究；2.参与了糖尿病肾病早期诊断标志物的研究。

信中

7

副教授

首都医科大学附属北京同仁医院

首都医科大学附属北京同仁医院

1.进行了糖尿病视网膜病变标准化的筛查流程、眼底照相标准、分级诊断标准的制定；2.进行了中国人群糖尿病视网膜病变患病率调查研究;3.参与ACE2与糖尿病发病机制的研究;4.参与了光学相干断层扫描用于自然人群糖尿病视网膜病变流行病学调查研究；5.参与项目技术的推广普及工作。

袁明霞

8

教授

首都医科大学附属北京友谊医院

首都医科大学附属北京同仁医院

负责项目的具体实施,主要学术（技术贡献）：1. 进行了糖尿病管理北京模式的研究，进行了中国人群糖尿病视网膜病变流行病学研究；参与项目技术的推广普及工作；参与了光学相干断层扫描用于自然人群糖尿病视网膜病变流行病学调查研究。

朱晓蓉

9

主治医师

首都医科大学附属北京同仁医院

首都医科大学附属北京同仁医院

负责项目的具体实施，主要学术（技术）贡献包括：进行了微血管病变检测新方法研究；参与了光学相干断层扫描用于自然人群糖尿病视网膜病变流行病学调查研究；参与了中国人群糖尿病视网膜病变流行病学研究。

刘畅

10

副主任医师

首都医科大学附属北京同仁医院

首都医科大学附属北京同仁医院

1.进行了ACE2与糖尿病发病机制相关研究；2.参与了糖尿病肾病早期诊断标志物的研究。

杨芳远

11

助理研究员

首都医科大学附属北京同仁医院

首都医科大学附属北京同仁医院

1.参与了ACE2和KCNH6与糖尿病发病机制相关研究；2.参与了糖尿病肾病早期诊断标志物的研究。

宋丽妮

12

医师

首都医科大学附属北京同仁医院

首都医科大学附属北京同仁医院

参与了ACE2与糖尿病发病机制相关研究。

 

2.主要知识产权和标准规范等目录：

知识产权（标准）类别

知识产权（标准）具体名称

国家

（期刊）

授权日期

授权号

（标准编号）

发明人（第一作者/通讯作者）

专利

ACE2在调控棕色脂肪组织活性中的应用

中国

2020.10.16

ZL 2017 1 0795756.3

杨金奎，曹曦，史婷婷

论著

Hyper- to Hypoinsulinemia and Diabetes: Effect of KCNH6 on Insulin Secretion

Cell reports

 

2018,25(13):3800.

杨金奎，卢晶，元莎莎，阿叁

专利

一种用于糖尿病肾病早期诊断的试剂盒

中国

2018.11.6

ZL201710507989.9

胡容，王忠亮，吴才桂，陈军超，陈兴，陈一凡

论著

Hepatic CREBZF Couples Insulin to Lipogenesis by Inhibiting Insig activity and Contributes to Hepatic Steatosis in Diet-Induced Insulin-Resistant Mice

Hepatology

 

2018 ，68(4):1361-1375

张菲菲/李于

专利

一种调控棕色脂肪组织活性的方法

中国

2020.10.16

ZL 2017 1 0795804.9

杨金奎，曹曦，史婷婷

论著

Post-translational regulation of lipogenesis via

AMPK-dependent phosphorylation of insulin-induced gene

Nature Communications

 

2019,

10(1):623

Han Yami, Ho Chi Minh / Li Yu

Paper

Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.

Nature Communications

 

12, 5616 (2021)

Zhao Miaomiao / Yang Jinkui

Paper

Urine Proteome Specific for Eye Damage Can Predict Kidney Damage in Patients With Type 2 Diabetes: A Case-Control and a 5.3-Year Prospective Cohort Study.

Diabetes Care

 

2017, 40(2):253-260

Yang Jinkui

Paper

Low prevalence of diabetic retinopathy in a Chinese population.

Diabetes Care

 

betes care 2012, 35(8):e61.

Yuan Mingxia / Yang Jinkui

Paper

CREBZF as a Key Regulator of STAT3 Pathway in the Control

of Liver Regeneration in Mice

Hepatology

 

2020 , 71(4):1421-1436

Ho Chi Minh, Han Yami / Li Yu

Related News

2024-01-22

Serving the big health industry, leapfrogging development of industry, academia and research - Anhui Huibang Biotech bloomed at the Anhui Traditional Chinese Medicine Academic Annual Conference

2023-08-07

Urine and nephropathy and defense -Dialogue column of the Diabetes Branch of the Chinese Medical Association

On August 4, 2023, the Chinese Medical Association Diabetes Branch 2023 Education Management Academic Conference was grandly held at Fengda International Hotel, Hefei City, Anhui Province.

2023-06-29

Good news! Huibang Biotechnology won the second prize of Science and Technology Progress Award of the Ministry of Education!

Recently, the Ministry of Education issued a certificate for the Outstanding Achievement Award (Science and Technology) of Scientific Research in Institutions of Higher Learning. Anhui Huibang Bioengineering Co., Ltd. jointly with the Chinese Academy of Sciences and Capital Medical University declared the project: "Research and Application of Molecular Targets for Diabetes" won the second prize of Science and Technology Progress Award of the Ministry of Education.

2023-06-12

Huibang Biotech actively implements the Hangzhou Declaration and contributes to building a healthy China

On June 11, 2023, the first China Health Promotion Conference was successfully held in Hangzhou. The conference was high-level and large-scale, and many guests from the government, medical and health circles, sports circles, education circles, science and technology circles, mass media, NGO organizations and business circles attended.

2023-06-01

Good news! Huibang Biotechnology won the "Star of Creation" Cup Innovative Product Gold Award

Wisdom medicine is upright and innovative | "Star of Creation" The 8th China Experimental Medicine Conference was grandly opened on May 27 at the Primus Hotel Conference Center in Nanchang! Huibang Bio's innovative product insulin-like growth factor binding protein-1/fetal fiber Connexin (IGFBP-1/fFN) detection kit won the 2022 "Innovation Star" Cup China Excellent Innovative Product Gold Award for In Vitro Diagnostics.